Ignite Creation Date:
2024-05-05 @ 4:49 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00320515
Status:
COMPLETED
Last Update Posted:
2009-09-28
First Post:
2006-04-28
Brief Title:
Study of Pemetrexed Plus Cisplatin in Advanced Gastric Cancer
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
Phase 12 Study of Pemetrexed Plus Cisplatin in Unresectable Advanced Gastric Carcinoma
Status:
COMPLETED
Status Verified Date:
2009-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multicenter single arm open-label Phase 12 study of pemetrexed plus cisplatin for patients with unresectable advanced gastric cancer who had no prior palliative chemotherapy Phase 1 was designed to determine the optimal dose of pemetrexed for its phase 2 which has been completed and now a total of 60 qualified patients will be enrolled in the phase 2 of this study The treating physician will determined the maximum number of cycles of pemetrexed plus cisplatin that a patient may receive in this study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H3E-AA-S038 | None | None | None |